Clinical Trial

HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

Study acronym: HYPAR
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Pancreatic resections carry a high risk for complications, especially pancreatic fistula. Both hydrocortisone and pasireotide have been shown to be effective in reducing complications in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these two drugs in preventing complications of pancreatic surgery.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2016-05-14; most recent amendment 2020-08-21.
Status change: Recruiting → Active, Not Recruiting 2019-03-03
Status change: Not Yet Recruiting → Recruiting 2016-12-04
Trial Details
NCT Number NCT02775227
Lead Sponsor Helsinki University Central Hospital
Conditions Pancreatic Fistula, Pancreatic Neoplasms
Enrollment 126 participants
Start Date 2016-05
Primary Completion 2019-01 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2020-08-24